PMID- 29808017
OWN - NLM
STAT- In-Data-Review
LR  - 20190126
IS  - 1532-1827 (Electronic)
IS  - 0007-0920 (Linking)
VI  - 119
IP  - 2
DP  - 2018 Jul
TI  - High-serum MMP-8 levels are associated with decreased survival and systemic
      inflammation in colorectal cancer.
PG  - 213-219
LID - 10.1038/s41416-018-0136-4 [doi]
AB  - BACKGROUND: Matrix metalloproteinase-8 (MMP-8) is a protease mainly expressed by 
      neutrophils that cleaves numerous substrates, including collagens and cytokines. 
      We have previously shown that serum MMP-8 levels increase in colorectal cancer
      (CRC) and correlate with distant metastasis. However, short follow-up in our
      prospective cohort did not enable survival analyses at the time of the first
      publication. METHODS: Preoperative serum MMP-8 levels were measured by
      immunofluorometric assay in 271 CRC patients and related to clinicopathological
      parameters, markers of systemic inflammation (modified Glasgow Prognostic Score, 
      mGPS; serum levels of C-reactive protein (CRP), albumin and 13 cytokines), the
      density of six types of tumour-infiltrating immune cells and survival. RESULTS:
      Increased MMP-8 levels associated with higher mGPS and higher serum levels of CRP
      and several cytokines, including IL-1ra, IL-7 and IL-8 (p < 0.001 for all). Serum
      MMP-8 negatively correlated with tumour-infiltrating mast cells (invasive margin:
      p = 0.005, tumour centre: p = 0.010). The patients with high-serum MMP-8 levels
      (>100 ng/mL) had poor cancer-specific survival, independent of tumour stage,
      grade, lymphatic invasion, patient age, BRAF VE1 immunohistochemistry, mismatch
      repair deficiency, Immunoscore and mGPS (multivariate HR 2.12, 95% CI 1.21-3.71, 
      p = 0.009). CONCLUSIONS: High-serum MMP-8 levels are associated with systemic
      inflammation and adverse outcome in CRC.
FAU - Sirnio, Paivi
AU  - Sirnio P
AD  - Cancer and Translational Medicine Research Unit, University of Oulu, POB 5000,
      90014, Oulu, Finland.
AD  - Oulu University Hospital and Medical Research Center Oulu, POB 21, 90029, Oulu,
      Finland.
FAU - Tuomisto, Anne
AU  - Tuomisto A
AD  - Cancer and Translational Medicine Research Unit, University of Oulu, POB 5000,
      90014, Oulu, Finland.
AD  - Oulu University Hospital and Medical Research Center Oulu, POB 21, 90029, Oulu,
      Finland.
FAU - Tervahartiala, Taina
AU  - Tervahartiala T
AD  - Department of Oral and Maxillofacial Diseases, University of Helsinki,
      Haartmaninkatu 8, POB 63, 00014, Helsinki, Finland.
FAU - Sorsa, Timo
AU  - Sorsa T
AD  - Department of Oral and Maxillofacial Diseases, University of Helsinki,
      Haartmaninkatu 8, POB 63, 00014, Helsinki, Finland.
FAU - Klintrup, Kai
AU  - Klintrup K
AD  - Oulu University Hospital and Medical Research Center Oulu, POB 21, 90029, Oulu,
      Finland.
AD  - Research Unit of Surgery, Anesthesia and Intensive Care, University of Oulu, POB 
      5000, 90014, Oulu, Finland.
FAU - Karhu, Toni
AU  - Karhu T
AD  - Research Unit of Biomedicine and Biocenter Oulu, Department of Physiology,
      University of Oulu, POB 5000, 90014, Oulu, Finland.
FAU - Herzig, Karl-Heinz
AU  - Herzig KH
AD  - Oulu University Hospital and Medical Research Center Oulu, POB 21, 90029, Oulu,
      Finland.
AD  - Research Unit of Biomedicine and Biocenter Oulu, Department of Physiology,
      University of Oulu, POB 5000, 90014, Oulu, Finland.
AD  - Department of Gastroenterology and Metabolism, Poznan University of Medical
      Sciences, ul. Szpitalna 27/33, 60-572, Poznan, Poland.
FAU - Makela, Jyrki
AU  - Makela J
AD  - Oulu University Hospital and Medical Research Center Oulu, POB 21, 90029, Oulu,
      Finland.
AD  - Research Unit of Surgery, Anesthesia and Intensive Care, University of Oulu, POB 
      5000, 90014, Oulu, Finland.
FAU - Karttunen, Tuomo J
AU  - Karttunen TJ
AD  - Cancer and Translational Medicine Research Unit, University of Oulu, POB 5000,
      90014, Oulu, Finland.
AD  - Oulu University Hospital and Medical Research Center Oulu, POB 21, 90029, Oulu,
      Finland.
FAU - Salo, Tuula
AU  - Salo T
AD  - Cancer and Translational Medicine Research Unit, University of Oulu, POB 5000,
      90014, Oulu, Finland.
AD  - Oulu University Hospital and Medical Research Center Oulu, POB 21, 90029, Oulu,
      Finland.
AD  - Department of Oral and Maxillofacial Diseases, University of Helsinki,
      Haartmaninkatu 8, POB 63, 00014, Helsinki, Finland.
AD  - Helsinki University Hospital, 00014, Helsinki, Finland.
FAU - Makinen, Markus J
AU  - Makinen MJ
AD  - Cancer and Translational Medicine Research Unit, University of Oulu, POB 5000,
      90014, Oulu, Finland.
AD  - Oulu University Hospital and Medical Research Center Oulu, POB 21, 90029, Oulu,
      Finland.
FAU - Vayrynen, Juha P
AU  - Vayrynen JP
AUID- ORCID: http://orcid.org/0000-0002-8683-2996
AD  - Cancer and Translational Medicine Research Unit, University of Oulu, POB 5000,
      90014, Oulu, Finland. juha.vayrynen@oulu.fi.
AD  - Oulu University Hospital and Medical Research Center Oulu, POB 21, 90029, Oulu,
      Finland. juha.vayrynen@oulu.fi.
LA  - eng
PT  - Journal Article
DEP - 20180529
PL  - England
TA  - Br J Cancer
JT  - British journal of cancer
JID - 0370635
PMC - PMC6048114
EDAT- 2018/05/29 06:00
MHDA- 2018/05/29 06:00
CRDT- 2018/05/30 06:00
PMCR- 2019/07/17 00:00
PHST- 2018/02/07 00:00 [received]
PHST- 2018/05/10 00:00 [accepted]
PHST- 2018/05/02 00:00 [revised]
PHST- 2019/07/17 00:00 [pmc-release]
PHST- 2018/05/29 06:00 [pubmed]
PHST- 2018/05/29 06:00 [medline]
PHST- 2018/05/30 06:00 [entrez]
AID - 10.1038/s41416-018-0136-4 [doi]
AID - 10.1038/s41416-018-0136-4 [pii]
PST - ppublish
SO  - Br J Cancer. 2018 Jul;119(2):213-219. doi: 10.1038/s41416-018-0136-4. Epub 2018
      May 29.